Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 26, 2005 Richard Gibbons	How to Outperform in 2005 Here are five tips to help investors identify stocks that are set to trounce the market.
The Motley Fool August 12, 2008 Charly Travers	The Mark of Winning Stocks Never underestimate the importance of a moat.
The Motley Fool October 8, 2004 Whitney Tilson	Blue-Chip Bargains? Sifting through beaten-down stocks may yield some good investments. But be careful, most of these stocks are that way for a reason.
The Motley Fool December 27, 2005	Foolish Fundamentals: Valuation Here's one way to calculate the value of any stock.
The Motley Fool January 15, 2008 Rich Greifner	I Like Big Moats and I Cannot Lie Do you know the most important thing Warren Buffett looks for when evaluating a company? The first thing Buffett looks for is an economic moat -- the bigger, the better.
The Motley Fool August 22, 2005 Richard Gibbons	Putting a Price on Tomorrow's Dollar Here's one way to calculate the value of any stock.
The Motley Fool March 7, 2006 Richard Gibbons	A Most Profitable Investment Idea Outlined in Benjamin Graham's The Intelligent Investor, there is one simple concept is the basis of stock market success.
The Motley Fool February 10, 2006 Tim Hanson	Good Stocks to Buy Now Put the market to work for you -- today: Altria... Abbot Labs... Bristol-Myers... Tootsie Roll... Pfizer... Coca-Cola... Merck...
The Motley Fool July 30, 2004 Whitney Tilson	The Tech Stock Opportunity Why the tech sector may be fertile ground for value investors.
The Motley Fool February 23, 2005 Stephen D. Simpson	Take Two on COX-2 FDA panel recommendations breathe new life into Merck and Pfizer's COX-2 pain medications. Looking ahead, investors should give a good, long look to the drug sector.
The Motley Fool June 23, 2005 Stephen D. Simpson	Dueling Fools: Merck Bear Looking at other big pharma peers, Merck is dead last when it comes to expected three- to five-year EPS growth. Why buy a troubled pharma when better options exist?
The Motley Fool September 21, 2004 Jeff Hwang	Find the Next Google The beauty of investing in a growth company is that, as long as you are looking to buy at a sufficient discount to your approximation of fair value, you have some leeway.
The Motley Fool May 13, 2005 John Reeves	The Next Ultimate Growth Stock There's a science and an art to growth investing.
The Motley Fool May 10, 2005	Fair Value, Explained Don't confuse a stock's price with its fair value.
The Motley Fool June 24, 2004 Tim Beyers	What Tech Bubble? The author disagrees that tech's highly overvalued. Investing in technology has long been a highly risky but profitable endeavor.
The Motley Fool December 21, 2006 Brian Lawler	Dueling Fools: Merck Bull Rebuttal Plenty of cash. Big pipeline. Not to worry. The future can't be predicted, but Merck's history shows its ability to weather even the toughest pharmaceutical-development environments.
The Motley Fool January 26, 2006 Rich Duprey	Will Acquisitions Patch Merck's Pipeline? The pharmaceutical giant announces a biotech shopping spree. A few key acquisitions that contribute late-stage drugs and significant revenue might be all Merck needs to keep its pipeline open. Investors, take note.
The Motley Fool December 1, 2010 Gerard Torres	Software Companies With Staying Power Everything you wanted to know about moats, but were afraid to ask.
The Motley Fool December 21, 2006 Ryan Fuhrmann	Dueling Fools: Merck Bear Rebuttal Yes, Merck is a good company, but investors can still do better.
The Motley Fool May 23, 2005 John Reeves	The Best Analyst Money Can Buy One of the keys to successful investing is knowledge. For other stocks that may or may not become value opportunities in the future, it would be ideal if you did your homework ahead of time. That way, you are ready when the situation arises.
The Motley Fool January 8, 2004 Selena Maranjian	Is That Stock Priced Too High? Some steep prices are too steep.
The Motley Fool November 19, 2004 Whitney Tilson	The Perfect Business Understanding the quality of a business is critical to being a successful investor, as it is a major determinant of what one should be willing to pay for a stock.
The Motley Fool October 4, 2004 Mathew Emmert	Got Merck? The pharmaceutical's investors can't seem to catch a break.
The Motley Fool December 21, 2006 Brian Lawler	Dueling Fools: Merck Bull What you are getting with Merck is one of the best-managed pharmas out there that will be experiencing solid double-digit earnings growth in the not-too-distant future with a smart dividend payout.
The Motley Fool April 13, 2005 Philip Durell	Dirt-Cheap Dream Stocks Who says value investing can't be glamorous?
The Motley Fool September 30, 2004 W. D. Crotty	Merck Chokes Back Vioxx The $2.3 billion arthritis drug is withdrawn from the market after clinical studies point to dangerous side-effects. Despite the bad news, Merck's big dividend payouts don't appear to be in jeopardy at the moment.
The Motley Fool August 26, 2005 Stephen D. Simpson	Merck Broaches the Obvious Merck will naturally end up settling many Vioxx cases, but the details are far from clear at this point. Investors, take note.
The Motley Fool October 23, 2006 Brian Lawler	Merck Mints Money The pharmaceutical hangs on, despite ongoing Vioxx woes. Conservative investors may do best to stay away from Merck until a lower share-price opportunity presents itself, now that shares are no longer sporting such a large Vioxx discount.
The Motley Fool September 15, 2006 Selena Maranjian	How to Spot Great Stocks You won't get great performance unless you invest in great companies. Investors, if you're patient, you'll likely find one or more on sale every now then.
The Motley Fool April 7, 2005 Richard Gibbons	Profit From Pessimism Stocks can become undervalued because of bad news, or even because a company is temporarily out of favor. When the market becomes unreasonably pessimistic about a company, investors can make huge profits.
The Motley Fool January 2, 2004 Zeke Ashton	New Year's Resolutions for Investors January is a traditional time for resolutions for the New Year. Here are 10 resolutions for investors to help cut down on mistakes, shape up portfolios, and achieve financial goals.
The Motley Fool July 19, 2004 Rick Aristotle Munarriz	eBay, Be Mine Still growing quickly, eBay managed to grow revenues by 59% this past quarter as topping the $3 billion sum for the entire year appears to be all but a given.
The Motley Fool April 21, 2006 Ryan Fuhrmann	One Very Useful Metric How do savvy investors balance growth and value?
The Motley Fool July 24, 2006 Stephen D. Simpson	Wait for a Bad Day at Merck Merck has value as a going concern, but investors should wait for some bad news to make the stock cheaper.
The Motley Fool October 7, 2004 Brian Gorman	Pfizer Will Weather the Storm The company will likely come out on top regardless of the outcome of the latest controversies. Pfizer remains a quality choice for long-term investors.
The Motley Fool January 25, 2006 Tim Hanson	Find the Silver Lining Falling stock prices don't have to be all bad news. While market drops can test your will, it's always best to keep a level head.
The Motley Fool January 25, 2005 Stephen D. Simpson	Prognosis Good for Merck The pharmaceutical weathered a tough year but should ride out its Vioxx troubles. While strict value investors may be put off, risk-tolerant investors can buy these shares today.
The Motley Fool July 8, 2004 Selena Maranjian	A Time to Sell There are lots of times when selling is best, such as when you don't know enough about the company or don't expect to make much more on the stock.
The Motley Fool October 24, 2005 Stephen D. Simpson	Merck Needs to Take Its Medicine It will be a long, long time before business at the pharmaceutical returns to business as usual. Turnarounds can pay off for patient investors.
The Motley Fool June 24, 2004	"Business Model" Explained Investors would do well to develop a solid understanding of the "business model" concept as they evaluate potential investments.
The Motley Fool April 29, 2005 David Gardner	Searching for Rule Breakers Find the great growth stocks of tomorrow a day early.
The Motley Fool February 4, 2005 Selena Maranjian	Embracing a Foolish Inconsistency As you begin, investing can be simple. Your first steps should be to get out of debt, read broadly on investing, and perhaps invest your initial dollars in an index fund.
The Motley Fool June 10, 2004 Selena Maranjian	Profiting From My Mistakes If you want to make a profit, then do as I say, not as I've done. The author has been investing for a decade now, and she's made her share of missteps along the way. Take time to learn from her mistakes so you can avoid the same pitfalls.
The Motley Fool June 23, 2005 Stephen D. Simpson	Dueling Fools: Merck Bear Rebuttal There's a reason why Merck's stock is cheap: weak pipeline, weak prospects.
The Motley Fool February 22, 2005 Charly Travers	Is Big Pharma a Bargain? While much of the drug sector is looking pretty tasty, Pfizer, with its attractive relative valuation, dominant marketing presence, and willingness to buy up blockbuster drugs, heads the list.
The Motley Fool November 12, 2004 Chuck Saletta	Three Magical Words Margin of safety are the three most important words in value investing.
The Motley Fool June 23, 2005 Rich Smith	Dueling Fools: Merck Bull It's hard to argue with a price this cheap. With a price-to-free cash flow ratio of less than 11, Merck's a steal.
The Motley Fool August 18, 2010 Rich Greifner	Is Activision Blizzard Built to Last? Can this company sustain its competitive advantages?
The Motley Fool May 4, 2005 Paul Elliott	This Little Trick Might Work If you take stock tips, you'd better know who you're talking to. This small-cap enthusiast plumbs the psyche of one highly touted stock picker for the method to his madness.
The Motley Fool October 11, 2004 Roger Nusbaum	Pfizer: Prognosis Critical This American icon seems destined to lag for the forseeable future.